.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,220,742

« Back to Dashboard

Claims for Patent: 7,220,742

Title:Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
Abstract: The present invention relates to enantiomerically pure compounds of general formula 1 ##STR00001## wherein the groups R.sup.1, R.sup.2, R.sup.3, R.sup.4 and X.sup.- may have the meanings given in the claims and in the specification, processes for preparing them and the use thereof as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints.
Inventor(s): Lustenberger; Philipp (Warthausen, DE), Konetzki; Ingo (Warthausen, DE), Sieger; Peter (Mittelbiberach, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim, DE)
Application Number:11/128,032
Patent Claims: 1. A compound of formula 1 ##STR00015## wherein the compound of formula 1 has an enantiomeric purity of at least 85% ee, and wherein R.sup.1 is hydrogen, C.sub.1 C.sub.4-alkyl, C.sub.1 C.sub.4-alkoxy, or halogen; R.sup.2 is hydrogen, C.sub.1 C.sub.4-alkyl, C.sub.1 C.sub.4-alkoxy, or halogen; R.sup.3 is hydrogen, C.sub.1 C.sub.4-alkyl, C.sub.1 C.sub.4-alkoxy, halogen, OH, --O--C.sub.1 C.sub.4-alkylene-COOH, or --O--C.sub.1 C.sub.4-alkylene-COO--C.sub.1 C.sub.4-alkyl; R.sup.4 is hydrogen, C.sub.1 C.sub.4-alkyl, C.sub.1 C.sub.4-alkoxy, or halogen; and X.sup.- is an anion with a single negative charge, optionally in the form of the tautomers, mixtures of the tautomers, hydrates, or solvates thereof.

2. The compound of formula 1 according to claim 1, wherein: R.sup.1 is hydrogen or halogen; R.sup.2 is hydrogen or halogen; R.sup.3 is hydrogen, C.sub.1 C.sub.4-alkoxy, or halogen; R.sup.4 is hydrogen or halogen; and X.sup.- is an anion with a single negative charge, optionally in the form of the tautomers, mixtures of the tautomers, hydrates, or solvates thereof.

3. The compound of formula 1 according to claim 1, wherein: R.sup.1 is hydrogen, fluorine, or clorine; R.sup.2 is hydrogen, fluorine, or clorine; R.sup.3 is hydrogen, methoxy, ethoxy, fluorine, or chlorine; R.sup.4 is hydrogen, fluorine, or chlorine; and X.sup.- is an anion with a single negative charge, optionally in the form of the tautomers, mixtures of the tautomers, hydrates, or solvates thereof.

4. The compound of formula 1 according to claim 1, wherein: R.sup.1 is hydrogen or fluorine; R.sup.2 is hydrogen; R.sup.3 is methoxy, ethoxy, or fluorine; R.sup.4 is hydrogen; and X.sup.- is chloride, bromide, sulphate, methanesulphonate, maleate, acetate, benzote, citrate, salicylate, trifluroacetate, fumarate, tartrate, or succinate; optionally in the form of the tautomers, mixtures of the tautomers, hydrates, or solvates thereof.

5. The compound of formula 1 according to claim 1, wherein: R.sup.1 is hydrogen; R.sup.2 is hydrogen, fluorine, or chlorine; R.sup.3 is hydrogen; R.sup.4 is hydrogen, fluorine, or chlorine; X.sup.- is chloride, bromide, sulphate, methanesulphonate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate, or succinate; optionally in the form of the tautomers, mixtures of the tautomers, hydrates, or solvates thereof.

6. The compound of formula 1 according to claim 1, wherein the compound is in crystalline form, optionally in the form of their crystalline tautomers, crystalline hydrates, or crystalline solvates.

7. A pharmaceutical composition comprising the compound of formula 1 according to claim 1 and a pharmaceutically acceptable carrier.

8. A method for the treatment of respiratory complaints comprising administering to a patient in need thereof a therapeutically effective amount of the compound of formula 1 according to claim 1.

9. A compound of formula 5 ##STR00016## wherein OPG is a hydroxyl function protected by a protective group PG, wherein OPG is --O--C.sub.1 C.sub.4-alkyl, --O-benzyl, or --O--CO--C.sub.1 C.sub.4-alkyl.

10. A compound of formula 7 ##STR00017## wherein: OPG is a hydroxyl function protected by a protective group PG, wherein OPG is --O--C.sub.1 C.sub.4-alkyl, --O-benzyl, or --O--CO--C.sub.1 C.sub.4-alkyl; and wherein: R.sup.1 is hydrogen, C.sub.1-C.sub.4-alkyl, C.sub.1-C.sub.4-alkoxy, or halogen; R.sup.2 is hydrogen, C.sub.1-C.sub.4-alkyl, C.sub.1-C.sub.4-alkoxy, or halogen; R.sup.3 is hydrogen, C.sub.1-C.sub.4-alkyl, C.sub.1-C.sub.4-alkoxy, halogen, OH, -O-C.sub.1-C.sub.4-alkylene-COOH, or -O-C.sub.1-C.sub.4-alkylene-COO-C.sub.1-C.sub.4-alkyl; R.sup.4 is hydrogen, C.sub.1-C.sub.4-alkyl, C.sub.1-C.sub.4-alkoxy, or halogen.

11. The compound according to claim 1, wherein the anion with the single negative charge is chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, malcate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate, oxalate, succinate, or p-toluenesulphonate.

12. The compound according to claim 2, wherein the anion with the single negative charge is chloride, bromide, iodide, sulphate, phosphate, methanesulphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate, oxalate, succinate, or p-toluenesulphonate.

13. The compound according to claim 3, wherein the anion with the single negative charge is chloride, bromide, iodide, sulphate, phosphate, methanesuiphonate, nitrate, maleate, acetate, benzoate, citrate, salicylate, trifluoroacetate, fumarate, tartrate, oxalate, succinate, or p-toluenesulphonate.

14. A method for the treatment of respiratory complaints comprising administering to a patient in need thereof a therapeutically effective amount of the compound of formula 1 according to claim 2.

15. A method for the treatment of respiratory complaints comprising administering to a patient in need thereof a therapeutically effective amount of the compound of formula 1 according to claim 3.

16. A method for the treatment of respiratory complaints comprising administering to a patient in need thereof a therapeutically effective amount of the compound of formula 1 according to claim 4.

17. A method for the treatment of respiratory complaints comprising administering to a patient in need thereof a therapeutically effective amount of the compound of formula 1 according to claim 5.

18. A method for the treatment of respiratory complaints comprising administering to a patient in need thereof a therapeutically effective amount of the compound of formula 1 according to claim 6.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc